memantine / Generic mfg. - LARVOL DELTA

Memantine, acetylcholinesterase inhibitors, and quality-of-care outcomes among patients with cognitive impairment: an emulated trial design. (PubMed, Alzheimers Dement (N Y)) - "Memantine and AChEIs were associated with adverse outcomes, and residual confounding was unlikely to fully account for all the observed associations."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Depression • Psychiatry

Intracellular Crosstalk Between NMDA and Sigma-1 Receptors: A Novel Mechanistic Insight Relevant to Neuropsychiatric Pharmacotherapy. (PubMed, Cells) - "Experimental data demonstrate that pharmacological agents initially characterized as NMDAR antagonists-such as ketamine, dextromethorphan, and memantine-also interact with σ1R, suggesting that their therapeutic efficacy may arise from coordinated modulation of both receptor systems. These findings collectively indicate that the σ1R is a key regulatory element enabling proper NMDAR function and that disruption of this interaction may contribute to excitatory imbalance implicated in the pathophysiology of neuropsychiatric disorders. Recognizing the σ1R-NMDAR crosstalk as an integrated signaling axis may thus inform the development of dual-target therapeutic strategies aimed at improving neuronal resilience and clinical outcomes in psychiatric and neurodegenerative diseases."

Journal • Review • Addiction (Opioid and Alcohol) • B Cell Lymphoma • CNS Disorders • Lymphoma • Mental Retardation • Oncology • Psychiatry • BCL2

To Study the Effect of Nilotinib, a Tyrosine Kinase Inhibitor, on Learning and Memory and Its Comparison with Nitric Oxide Synthase Inhibitor in an Animal Model of Alzheimer's Disease. (PubMed, Ann Neurosci) - "This study aimed to compare the effect of nilotinib (a tyrosine kinase inhibitor) and N ω-nitro-l-arginine methyl ester (L-NAME, a nitric oxide synthase inhibitor) as agents that improve learning and memory processes in a scopolamine-induced rat model of AD with memantine. Nilotinib demonstrated superior efficacy to L-NAME and may represent a potential therapeutic strategy for AD. Further studies are warranted to evaluate long-term effects and clinical applicability."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Pain

Memantine-Induced Cholestasis and Acute Hepatitis in an 8-Week-Old Term Infant. (PubMed, ACG Case Rep J) - "We present an 8-week-old term male infant with cholestasis secondary to breast milk transference of memantine. To the best of our knowledge, this is the first case associated with cholestasis and acute hepatitis with memantine transference through breast-feeding."

Journal • Cholestasis • Hepatology • Inflammation

MemoryRT: Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: The University of Texas Health Science Center at San Antonio | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2031 ➔ Jul 2031 | Initiation date: Mar 2026 ➔ Jul 2026 | Trial primary completion date: Mar 2030 ➔ Jul 2030

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Brain Cancer • Oncology • Solid Tumor

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: Duke University | Trial completion date: Nov 2026 ➔ Sep 2027 | Trial primary completion date: Nov 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Real-world use and evaluation of a generative AI chatbot for Parkinson’s disease information: a prospective observational study. (PubMed, Lancet Reg Health Eur) - "Confirmed critical events-five flagged, four sampled-spanned three failure classes (knowledge boundary, robustness, and escalation failures) and included an inappropriate memantine recommendation in Parkinson's disease dementia and explicit suicidal ideation that did not trigger the intended emergency response. Tightly scoped, retrieval-augmented, patient-facing AI achieved favourable automated triage classifications while still harbouring clinically critical failures invisible to automated quality metrics alone; detecting them required conversation-level evaluation with clinical expert adjudication. Deutsche Forschungsgemeinschaft, Interdisciplinary Center for Clinical Research Würzburg, and German Ministry of Education and Research (BMBF); technical development of jAImes was commissioned and financed by Parkinson Stiftung Deutschland."

Journal • Observational data • Real-world evidence • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease • Psychiatry • Suicidal Ideation

Memantine and its analogs: Potential applications in cancer therapy. (PubMed, Adv Cancer Res) - "The adamantane scaffold in memantine has proved to be a versatile tool for the discovery of synthetic memantine analogs with robust anti-cancer activity. The discovery of second-generation memantine analogs may have wider applications in combating cancer recurrence and addressing clinical challenges in the treatment of drug-resistant and metastatic cancers."

Journal • Review • CNS Disorders • Dementia • Fatigue • Oncology • Pain

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer (clinicaltrials.gov) - P2/3 | N=12 | Recruiting | Sponsor: Inova Health Care Services | Trial completion date: Aug 2026 ➔ Jul 2029 | Trial primary completion date: Jul 2026 ➔ Jul 2028

Trial completion date • Trial primary completion date • Fibrosis • Hepatocellular Cancer • Immunology • Liver Cancer • Liver Cirrhosis • Oncology • Solid Tumor

NRG-CC009: Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability (clinicaltrials.gov) - P3 | N=152 | Active, not recruiting | Sponsor: NRG Oncology | Recruiting ➔ Active, not recruiting

Enrollment closed • Brain Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Escalating Doses of Memantine in Down Syndrome (MEDS-123) (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: University Hospitals Cleveland Medical Center | Initiation date: Jun 2026 ➔ Oct 2026

Trial initiation date • Developmental Disorders • Genetic Disorders • Mental Retardation

Mechanisms of NMDA receptor inhibition by fluoroethylnormemantine - comparison with memantine. (PubMed, Eur J Pharmacol) - "Faster kinetics and moderate activity, still within micromolar range, might alleviate side effects known for MEM. The obtained parameters, as well as the details of mechanisms of action, extend our view of FENM interaction with NMDARs, helping in its development as a new neuroprotective drug."

Journal • Alzheimer's Disease • CNS Disorders

Clozapine-Memantine Therapy in Catatonia: Clinical Insights From a Case Report and Literature Review. (PubMed, Clin Neuropharmacol) - "This case demonstrates that clozapine can serve as a viable alternative treatment for catatonia when standard interventions are unavailable or contraindicated. Memantine may offer additional therapeutic benefits; however, further research is required to establish its efficacy. The rarity of similar cases in the literature further highlights the uniqueness of the present clinical scenario."

Journal • Cardiovascular • CNS Disorders • Psychiatry • Schizophrenia • Vascular Neurology

Efficacy and safety of memantine in adults with amyotrophic lateral sclerosis: a systematic review and meta-analysis. (PubMed, J Neural Transm (Vienna)) - "Current evidence does not support its use as a disease-modifying or adjunctive therapy. Trial registration: PROSPERO CRD420261277874."

Journal • Retrospective data • Review • Amyotrophic Lateral Sclerosis • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

Psychotropic Polypharmacy in Alzheimer's Disease: A Potentially Inappropriate Medication Perspective in Older Adults. (PubMed, Curr Alzheimer Res) - "This review specifically examines anticholinergic drugs, antipsychotics, benzodiazepines and Z-drugs, tricyclic antidepressants, and select newer antidepressants-including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), mirtazapine, trazodone, and paroxetine-guided by the 2023 American Geriatrics Society (AGS) Beers Criteria®. Current evidence indicates that these medications may contribute to cognitive decline through anticholinergic burden, sedation, and pharmacodynamic interactions with cholinesterase inhibitors, such as donepezil and memantine...This study also summarizes current nonpharmacological strategies and proposes a structured clinical medication review framework. Overall, this review highlights the importance of minimizing inappropriate psychotropic use in AD, prioritizing non-pharmacological interventions, and conducting individualized risk-benefit assessments in clinical practice."

Journal • Alzheimer's Disease • Anesthesia • CNS Disorders • Dementia • Psychiatry

A 6-Year-Old With Becker Muscular Dystrophy and Catatonia. (PubMed, Pediatrics) - "He received many medication treatments for catatonia, including escalating doses of lorazepam and augmentation with memantine, zolpidem, quetiapine, and ultimately clozapine, without adequate symptom improvement and with side effects including significant weight gain. This case highlights the importance of the identification of catatonia to guide evidence-based treatment and the value of timely access to electroconvulsive therapy for pediatric patients. While the etiology of his catatonia remains undetermined, his diagnosis of BMD could play a role and further supports the importance of a comprehensive medical work-up."

Journal • Becker Muscular Dystrophy • CNS Disorders • Duchenne Muscular Dystrophy • Immunology • Muscular Dystrophy • Pediatrics • Psychiatry

Nanoscale localisation of memantine governs structural modulation and loading in bicontinuous cubic phase systems. (PubMed, J Colloid Interface Sci) - "These findings show that the adamantane scaffold alone is insufficient to ensure efficient incorporation into cubic phases. Localisation, accommodation, and retention are governed by the balance between hydrophobic anchoring and the hydration demands of attached functionalities, establishing a mechanistic framework for predicting the behaviour of amphiphilic adamantane-containing therapeutics in non-lamellar lipid nanocarriers."

Journal • Alzheimer's Disease • CNS Disorders

Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms with Hippocampal Avoidance during Whole-Brain Radiotherapy for Brain Metastases: Final Results of NRG Oncology CC001. (PubMed, Int J Radiat Oncol Biol Phys) - "With median follow-up exceeding one-year, HA during WBRT+memantine for brain metastases leads to sustained preservation of cognitive function and continued prevention of patient-reported neurologic symptoms, symptom interference and cognitive symptoms with no difference in survival or toxicity."

Journal • Brain Cancer • Oncology • Solid Tumor

Primary Endpoint Results of NRG CC003: Phase IIR/III Trial of Prophylactic Cranial Irradiation (PCI) with or without Hippocampal Avoidance (HA) for Small Cell Lung Cancer (SCLC) (ASTRO 2023) - "While the study did not meet its HVLT-DR failure primary endpoint, HA during PCI prevents NCF failure with non-inferior ICR risk and similar survival. The NCF benefit of HA was independent of non-significant higher NCF failure risk with memantine use. Worse verbal word fluency, assessed using COWA, following HA-PCI requires further investigation given baseline between-arm imbalance in COWA scores."

Late-breaking abstract • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

Evaluating the Heterogeneity of Hippocampal Avoidant Whole Brain Radiotherapy Treatment Effect: A Secondary Analysis of NRG CC001. (PubMed, Neuro Oncol) - "Differential neuroprotective response to HA-WBRT was identified in this analysis. Patients surviving ≥ 4 months derived benefit from HA-WBRT. There is evidence of heterogeneity of treatment effect for patients with less severe patient-reported cognitive impairment at baseline and those with primary lung histology."

Heterogeneity • Journal • Alzheimer's Disease • Brain Cancer • Cognitive Disorders • Oncology • Solid Tumor

Neurocognitive Outcome of Conformal Whole Brain Radiotherapy with Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial (ASTRO 2024) - "The initial analysis demonstrates that patients with multiple brain metastases receiving left-sided unilateral conformal HA-WBRT have an equivalent effect in neurocognitive function preservation compared to those receiving the standard bilateral HA-WBRT."

Clinical • Late-breaking abstract • P2 data • Brain Cancer • Lung Cancer • Oncology • Solid Tumor

Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. (PubMed, J Clin Oncol) - "Although the study did not meet its primary end point of DR preservation, HA during PCI reduces the risk of overall neurocognitive toxicity with noninferior ICR risk and similar survival."

Journal • P2/3 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Initial report of memory avoidance whole brain radiotherapy to treat brain metastases: A prospective phase 2 trial. (ASCO 2025) - P=N/A | "The cognitive decline rate of approximately 17% at three months for patients receiving MA-WBRT compares favorably to a 3-month cognitive decline rate of 50% seen on NRG CC001. Additionally, MA-WBRT does not appear to significantly increase the risk of intracranial failure. Further evaluation of the delayed impact ( > 6 months) of MA-WBRT on cognitive function will be reported when data are available."

Clinical • P2 data • CNS Disorders • Lung Cancer • Mental Retardation • Oncology • Psychiatry • Solid Tumor

Combined low-dose (2R,6R)-Hydroxynorketamine and memantine restore BDNF/TrkB signaling and synaptic function in an LPS-induced model of depressive-like behavior in male mice. (PubMed, Brain Behav Immun) - "Together, these findings suggest that MEM and low-dose HNK counteract inflammation-associated neural dysfunction in association with Trk-related signaling. These proof-of-concept findings do not establish a safety or overall drug-burden advantage over full-dose HNK and require validation in both sexes before translational advantages can be inferred."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Mood Disorders • Psychiatry

Symptomatic treatment for Alzheimer disease: current evidence and future directions. (PubMed, Nat Rev Neurol) - "Established pharmacological treatments, notably cholinesterase inhibitors and memantine, deliver modest but significant benefits, with biomarker-stratified analyses suggesting the greatest benefit in individuals with confirmed AD pathology...Newer agents, including brexpiprazole for agitation and pimavanserin for psychosis, show promise but require careful interpretation of effect size and safety. Future progress will depend on biomarker-informed patient selection, integration of circuit-level measures, rational combination strategies spanning pharmacological and non-pharmacological modalities, and adoption of patient-centred outcomes. Symptomatic therapies will remain essential for improving quality of life in people with AD, even as disease-targeted therapies reshape disease trajectories."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Psychiatry